<code id='50EDBBC06A'></code><style id='50EDBBC06A'></style>
    • <acronym id='50EDBBC06A'></acronym>
      <center id='50EDBBC06A'><center id='50EDBBC06A'><tfoot id='50EDBBC06A'></tfoot></center><abbr id='50EDBBC06A'><dir id='50EDBBC06A'><tfoot id='50EDBBC06A'></tfoot><noframes id='50EDBBC06A'>

    • <optgroup id='50EDBBC06A'><strike id='50EDBBC06A'><sup id='50EDBBC06A'></sup></strike><code id='50EDBBC06A'></code></optgroup>
        1. <b id='50EDBBC06A'><label id='50EDBBC06A'><select id='50EDBBC06A'><dt id='50EDBBC06A'><span id='50EDBBC06A'></span></dt></select></label></b><u id='50EDBBC06A'></u>
          <i id='50EDBBC06A'><strike id='50EDBBC06A'><tt id='50EDBBC06A'><pre id='50EDBBC06A'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:746
          Sammy Kimball for STAT

          Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

          advertisement

          For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          As pharma fights Medicare drug negotiation, hospitals, docs silent
          As pharma fights Medicare drug negotiation, hospitals, docs silent

          AdobeThepharmaceuticalindustryhasbeenupinarmsoverMedicare’sfirstlistof10prescriptiondrugsthatwillbes

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Changes to biosimilar regulatory framework must prioritize patients

          JUANMABROMATA/AFPviaGettyImagesBiosimilarsarenolongeranewanduntestedclassofmedicines.Today,theyprovi